Pegtarazimod limits acute graft-versus-host disease mortality in mice, showing tolerability in human patients.
Pegtarazimod limits acute graft-versus-host disease mortality and severity in mice and is tolerated in patients.
Abstract
Pegtarazimod significantly reduced acute graft-versus-host disease (aGVHD) mortality and severity in mice, also demonstrating tolerability in human patients.